Literature DB >> 1429668

Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.

A S Ribba1, J Voorberg, D Meyer, H Pannekoek, G Pietu.   

Abstract

Type IIA and IIB von Willebrand disease (vWD) result from defects in von Willebrand factor (vWF). Although both type IIA and IIB vWD are characterized by the absence of high molecular weight multimers in plasma, vWF from patients with type IIA vWD demonstrates a decreased affinity for the platelet receptor glycoprotein Ib (GPIb), whereas vWF from patients with type IIB vWD show an increased affinity for GPIb. To investigate how structural alterations in vWF affect its interaction with GPIb, we reproduced the reported potential mutations in type IIA and IIB vWD in vWF cDNA and expressed the recombinant proteins in COS-1 cells. The type IIA vWF potential mutation was represented by a G-->A transversion which results in the substitution of Lys for Glu at position 875 in the mature vWF subunit (rvWFLys875). The type IIB vWF mutation corresponds to a duplicated ATG codon, resulting in three contiguous methionines starting at position 540-541 in the normal vWF sequence (rv-WFduplMet540-541). The subunit composition and multimeric structure of both mutant proteins were similar to the wild-type rvWF. The rvWFLys875 bound to fixed platelets in the presence of ristocetin similar to wild-type rvWF. The rvWFduplMet540-541 bound to fixed platelets in the absence of agonist. The rvWFLys875 appears to interact normally with GPIb, and the decreased affinity for the platelet receptor observed in plasma is probably a consequence of prior reduction in multimeric size resulting from the defect. In contrast, the duplication of Met540-541 increases the reactivity of vWF for its platelet receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1429668

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Mechanisms by which von Willebrand disease mutations destabilize the A2 domain.

Authors:  Amy J Xu; Timothy A Springer
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

Review 2.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 3.  Biology and physics of von Willebrand factor concatamers.

Authors:  T A Springer
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

4.  Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor.

Authors:  Qing Zhang; Yan-Feng Zhou; Cheng-Zhong Zhang; Xiaohui Zhang; Chafen Lu; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-21       Impact factor: 11.205

Review 5.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

6.  Structural basis of type 2A von Willebrand disease investigated by molecular dynamics simulations and experiments.

Authors:  Gianluca Interlandi; Minhua Ling; An Yue Tu; Dominic W Chung; Wendy E Thomas
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.